Blog

$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology

Photo taken from Race Oncology/X

Aug 2, 2024, 00:52

$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology

Race Oncology made the following post on X:

“$RAC is pleased to announce the successful conclusion of an investigator-sponsored Phase 1b/2 trial of bisantrene, with trial results showing the drug, in combination with clofarabine and fludarabine, has achieved its primary endpoint for efficacy.
More.”

Source: Race Oncology/X

$RAC bisantrene cancer cancer therapy cancer treatment clinical trial results clofarabine drug efficacy fludarabine Investigator-Sponsored trial OncoDaily Oncology oncology research Phase 1b/2 trial primary endpoint Race Oncology Research successful trial

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage